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1. Introduction  
One of the main challenges in chemotherapy is the delivery of effective doses of cytotoxic 
agents to the tumor site and simultaneously to minimize the side effects on normal cells. The 
use of drug delivery systems (DDS) can improve the pharmacological properties of many 
agents, modifying their pharmacokinetics and biodistribution. 
Among the DDS available, liposomes are one of the most used and promising. Cytotoxic 
drug incorporation into liposomes has been reported since 1970. Thanks to their special 
structure, they are able to encapsulate both hydrophilic and hydrophobic compounds. 
Today several drugs with various chemical properties (hydrophilic drugs such as N-
(phosphoacetyl)-L-aspartate or hydrophobic drugs such as doxorubicin) have been 
succesfully encapsulated into liposomes. Compared to conventional chemotherapeutic 
drugs (non-encapsulated), the encapsulation of these drugs into liposomes shows several 
advantages, such as a considerable reduction of side effects associated to conventional 
chemotherapy, increase of solubility, improvement of therapeutic index and prolonged 
duration of exposure (Papahadjopoulos, Allen et al., 1991; Drummond, Meyer et al., 1999). 
Moreover, tumours are one of the primary sites for accumulation of liposomes, where they 
concentrate due to the higher permeability of the vascular endothelium surrounding 
tumours. However, despite their unquestionable advantages, unfortunately, liposomes are 
non site-specific drug delivery systems. 
Antibody based targeted therapies are the most promising strategies to improve the 
selectivity and potency of current cancer treatments. The increasing number of new 
anticancer drugs based on antibodies demonstrates this assumption (Sznol & Holmlund, 
1997; Reichert, Rosensweig et al., 2005). However, selectivity provided by the use of 
antibodies can also be used, not only for direct treatment but to target other anticancer 
drugs. In this sense, the conjugation of complete or fragmented antibodies to liposomes has 
resulted in the next generation of drug delivery systems, i.e. immunoliposomes (Park, Hong 
et al., 1997; Noble, Kirpotin et al., 2004). In this strategy, the liposome acts as a drug carrier, 
and the antibody allows bringing the drug system specifically to its target. 
Tumour cells have few specific molecules for recognition as they share many common 
features with normal cells. Then, the main issue when designing selective 
immunoliposomes is to find a proper target. Since complete selectivity is hard to achieve, 
the target must be as selective as possible, i.e. by using tumor-overexpressed proteins as 
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targets. These proteins increase their expression levels up to 100 times compared to normal 
cells, and are suitable to be used as best target proteins (Barrajón-Catalán, Menéndez-
Gutiérrez et al., 2010). 
In this chapter, two promising targets are presented as examples of the immunoliposomes 
versatility and their usefulness in breast cancer models. The first one is the epithelial cell 
adhesion molecule (EpCAM), which is overexpressed in carcinomas of several origins 
including breast carcinomas (Armstrong & Eck, 2003; Went, Lugli et al., 2004). The second 
one is the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20–
30% of breast and ovarian cancers carrying a bad prognosis (Barrajón-Catalán, Menéndez-
Gutiérrez et al., 2010). Currently, several antibody-derived drugs based on these targets are 
already in use in cancer clinical therapies. For instance, Edrecolomab and Trastuzumab are 
antibodies against these proteins which are used in cancer therapies (Punt, Nagy et al., 2002; 
Reichert, Rosensweig et al., 2005). 
The diversity of chemotherapeutic drugs vehiculized into immunoliposomes is 
continuously growing, as new drugs or natural compounds are incorporated to the 
anticancer therapeutic arsenal (Mamot, Drummond et al., 2003; Yang, Choi et al., 2007; Yuji 
Yamamoto, 2011 Jan). Alternatively, other new strategies based on the use of 
immunoliposomes, but including lytic peptides, are focused on specifically promoting the 
lysis of cancer cells (Barrajón-Catalán, Menéndez-Gutiérrez et al., 2010). In this regard, 
melittin represents one of the most studied lytic peptides, and it has shown anti-
inflammatory and anticancer activities and low toxicity, and it has been used in several 
therapeutical approaches (Son, Lee et al., 2007; Soman, Baldwin et al., 2009). 
This chapter is focused on the latest mentioned type of immunoliposomes, the so-called lytic 
immunoliposomes (LILs), which might become a fast and specific new treatment for breast 
cancer. The feasibility of LILs carrying melittin and containing antibodies against the two 
above mentioned targets, EpCAM and HER2, is shown. These immunoliposomes have been 
used to treat a panel of human breast cancer cells bearing different EpCAM or HER2 
expression levels. In both cases, the morphological changes observed in treated cancer cells 
suggested a cytolytic process, as it could be expected given melittin lytic properties. 
The approach presented here may suppose a specific, versatile and effective strategy for the 
treatment of tumors overexpressing a surface antigen. The incorporation of new antibodies 
to this model will allow targeting additional molecular sites in cancer cells, which will 
surely provide treatments for cancer therapeutics with increased selectivity and lower side 
effects and, it will probably contribute to decrease the appearance of resistances. 
2. Preliminary aspects to be considered 
2.1 The molecular target 
As stated above, the most difficult task when designing immunoliposomes is choosing the 
right molecular target. Since complete selectivity is hard to achieve, the therapy must be 
as specific as possible in order to reduce side effects and to increase the potency of the 
model. 
To obtain optimal results, the target must fulfil the following conditions: 
 It must be a surface antigen and has to be located in an accessible domain of the 
cytoplasmic membrane. 
 It must be as much antigenic as possible in order to produce the corresponding 
antibody. 
www.intechopen.com
 
Immunoliposomes: A Multipurpose Strategy in Breast Cancer Targeted Therapy 
 
437 
 Proteins are preferred rather than other antigens such as carbohydrates. 
 Tumor specific antigens are preferred, but these are rare. Then, tumor overexpressed 
antigens are a more accessible alternative. The higher the overexpression level is, the 
more selective the system gets. 
Finding the perfect target is unlikely, but there are several promising candidates. The most 
used and characterized antigens belong to the HER family. Moreover, other targets have 
been used and well characterized: EpCAM in breast and gastric cancers (Cimino, Halushka 
et al., 2009; Wenqi, Li et al., 2009), PSMA in prostate cancer (Ikegami, Tadakuma et al., 2005; 
Ikegami, Yamakami et al., 2006) or MUC1 in colon and prostate cancer (McDermott, Crocker 
et al., 2001; Papadopoulos, Sivridis et al., 2001). 
The continuous discovery of new tumor specific and/or tumor overexpressed antigens by 
many research groups working in this field will enormously contribute to the development 
of these treatments, by generating a constant increase in the number of potential antibodies. 
Moreover, new advances in proteomic investigation will also help to establish successful 
therapies (Conrotto, Roesli et al., 2008; Madoz-Gúrpide, Kuick et al., 2008). 
2.2 The immunoliposome design 
The linking of antibodies to liposomes has been intensely studied from different perspectives 
(see review (Hansen, Kao et al., 1995)). Most of these techniques have been used in different 
cellular and animal models. Since every case may have specific requirements, the linking 
technology is normally chosen depending on the availability of the chemical groups involved, 
such as lipid polar head groups, linker’s nature and antibody characteristics. 
Once the technique is selected, the right linker will be chosen according to the procedure. 
The most common linkers are modified lipids containing the maleimide moiety. On the 
other hand, the antibody must be derivatized in order to be linked to the lipid moieties. One 
of the most common derivatization techniques uses Traut’s reagent, which yields thiol 
groups in the antibody, what allows the subsequent reaction with the maleimide group of 
the modified lipids through a covalent bonding (Kirpotin, Park et al., 1997). 
Regardless the selected protocol, there are some aspects to take into account when 
immunoliposomes are designed: 
 Immunogenicity of the final product must be as low as possible, and the drug must 
remain in blood circulation as long as possible. Pegylation solves both aspects in a 
smart way. First, the use of pegylated lipids into liposomes at 1-5% molar percentage 
increases blood permanence time because it reduces uptake rate by the 
reticuloendothelial system. Second, it decreases the immunogenicity of the preparation 
as the liposomes become “invisible” to the immune system due to the polyethylene 
glycol (PEG) tails (Petrak, 2005; Elbayoumi & Torchilin, 2006). In addition, pegylated 
liposomes show a superior tumor delivery capacity compared with conventional 
liposomes composed of natural phospholipids (Allen & Cullis, 2004). Although there 
are different PEG lengths, PEG-2000 is the most used in pharmacological preparations 
(Sadzuka, Kishi et al., 2003). 
 Lipid composition is also very important because it determines the fluidity of the 
liposomal membrane, and therefore, its ability to encapsulate or retain compounds. For 
example, the presence of cholesterol increases the rigidity of the liposome membrane, 
contributing to the encapsulation improvement of hydrophilic compounds into the 
inner aqueous cavity. When hydrophobic molecules are used, the lipid composition is 
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also an important issue, because it must provide an adequate environment, capable to 
retain hydrophobic molecules in the required active conformation and the ability to 
transfer them to target membranes (Maruyama, Kennel et al., 1990). 
 Finally, the antibody attached to the liposome can be used either as a whole protein or 
fragmented. Several approaches  have been developed using the single-chain antibody 
variable region (scFv) (Mamot, Drummond et al., 2003; Hu, Chen et al., 2006), the 
complete variable region (Fab) (Kirpotin, Drummond et al., 2006) or the whole antibody 
(Barrajón-Catalán, Menéndez-Gutiérrez et al., 2010). It must be considered that, scFv 
and Fab (Figure 1) are less immunogenic than the whole antibody, however these 
fragments are not easy to obtain. The production of Fab requires a large amount of the 
original antibody and the protocol includes its digestion by pepsin or other enzymes. In 
contrast, the use of scFv fragments requires cloning designs and recombinant 
production systems. 
 
 
Fig. 1. Different classes of antibody derivatives used for immunoliposome synthesis. Heavy 
chain (H) is shown in blue and light chain (L) in red, variable region appears as empty 
ellipses. Whole antibody (on the left) can be used to obtain the Fab fragment with constant 
and variable region linked by disulfide bonds. scFV fragment contains only the variable 
regions of both heavy and light chains bound by a linker. 
2.3 The lytic peptides 
Antimicrobial peptides are gene encoded natural peptide antibiotics being part of the innate 
defences of many organisms (Patrzykat & Douglas, 2005). Among them, lytic peptides (LPs) 
are those showing highest cytolytic activity. Several studies have shown that LPs have cationic 
and amphipathic properties, which allow them to interact with lipid cell membranes of most 
pathogens, often negatively-charged (Lohner & Blondelle, 2005), by forming pores or ion 
channels (Bechinger, 1997). Several models have been proposed to explain this mechanism, i.e. 
barrel-stave, carpet-like, toroidal pore formation or detergent-type micellization models 
(Allende, Simon et al., 2005). Regardless the molecular mechanism, LPs promote increased 
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membrane permeabilization, leakage of cell content and osmotic instability, which leads to the 
unavoidable cell death. In some cases, peptide diffusion to intracellular targets has also been 
described. The capacity of LPs to promote cell lysis has been extensively studied in order to 
develop new anticancer approaches (Hoskin & Ramamoorthy, 2008). 
LPs can be included in LILs as active molecules that promote cytotoxic effects. LPs have 
already been used covalently linked to hormone segments in order to increase their efficacy 
and selectivity on several types of cancer cells (Gawronska, Leuschner et al., 2002; Hansel, 
Enright et al., 2006). Nevertheless, a therapy based on this approach might be valid only for 
those tumors expressing hormone receptors, such as prostate or breast cancers. However, 
LILs may be applied to any kind of tumors. For instance, previous reports have shown the 
activity of LILs against hepatoma cancer cells (Hu, Chen et al., 2006). 
Among the LPs derived from insects and amphibians, melittin, from bee venom, has 
recently shown anticancer properties but its precise mechanism of action is still uncertain 
(Son, Lee et al., 2007). Melittin is a 26 amino acid linear peptide 
(GIGAVLKVLTTGLPALISWIKRKRQQ) with alpha-helix conformation. The distribution of 
its amino acid sequence is the main responsible of the amphipathic nature of this peptide: 
the amino-terminal region (residues 1–20) is predominantly formed by hydrophobic 
residues, whereas the carboxy-terminal region (residues 21–26) is hydrophilic due to the 
presence of a tandem of basic amino acids (Raghuraman & Chattopadhyay, 2007). Melittin 
has been the LP choice in several studies using LILs. Among the reasons for this are: its 
particular amphipatic nature, which allows it to bind to lipid membranes with high affinity, 
its activity against tumor cells, its relatively low market value and its availability. It is also 
water soluble, which facilitates its manipulation. 
Although melittin molecular mechanism seems to be controversial, the most accepted model 
proposes that melittin destroys target membranes by pore formation and destabilization 
through the barrel-stave mechanism (Sui, Wu et al., 1994; Lin & Baumgaertner, 2000). In this 
sense, once LIL binds to targeted cell, a lytic process occurs in a few hours with no signal of 
apoptosis (Barrajón-Catalán, Menéndez-Gutiérrez et al., 2010).  
To fully characterize LILs model, the selected LP must be adequately quantified. For this 
task, HPLC coupled to fluorescent, diode array or mass detection is the most commonly 
used method (Perez-Paya, Braco et al., 1991; Barrajón-Catalán, Menéndez-Gutiérrez et al., 
2010) but also capillary chromatography (Pacakova & Stulik, 2000) can be utilised. 
2.4 The cellular model 
The choice of a suitable cellular model is as important as the target to test the efficacy of the 
LIL system. Several cell lines showing gradual differences in the expression levels of the 
targeted protein may be required for these studies in order to make sure that cytotoxic 
effects are dependent on the antigen expression. Thus, one of the preliminary tasks is the 
quantification of the expression levels of the selected cellular lines. Nevertheless, it must be 
checked that all the quantified protein is located on the cell membrane. In some cases, a 
significant percentage of the overexpressed protein shows an intracellular location, and 
then, this protein is obviously not suitable to be used as target for LILs. Fortunately, many 
breast cancer cellular lines are readily available and well characterized, facilitating this task. 
When selecting cell lines, to assess their in vivo tumorogenic capacity becomes also an 
important issue. One of the critical steps in preclinical investigations with LILs and other 
pharmaceutical formulations, is to prove their in vivo activity against xenotransplanted 
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cancer cells in athymic mice. Not all cells are able to establish and grow in these mice on 
their own. For example, some breast cancer cells present strogen-dependent growth (Saceda, 
Knabbe et al., 1991) and estradiol must be used as coadjuvants in order to obtain successful 
in vivo tumourogenic activity. On the other hand, other cells need the use of polymeric 
coadjuvants, such as matrigel, to be implanted in mice and the tumor cells must be 
coinjected with this polymer. 
3. Lytic immunoliposome models 
3.1 EpCAM immunoliposomes 
EpCAM is a transmembrane protein (Armstrong & Eck, 2003; Went, Lugli et al., 2004; 
Trzpis, McLaughlin et al., 2007) which mediates epithelium-specific Ca2+ independent cell-
cell adhesions. EpCAM is overexpressed in carcinomas of several origins such as breast, 
gastric, colorectal, prostate and liver (Went, Lugli et al., 2004; Wenqi, Li et al., 2009). EpCAM 
antigen has been used in immunotherapy studies (Braun, Hepp et al., 1999; Winkler, Martin-
Killias et al., 2009) against breast cancer cells with good results. There is a commercial anti-
EpCAM antibody called Edrecolomab (Panorex ®), which is currently being used in the 
treatment of colorectal, breast and gastric cancers (Braun, Hepp et al., 1999; Haller, 2001). 
Due to these reasons, EpCAM supposes an attractive and promising target to be challenged 
through the use of lytic immunoliposomes therapy. 
In this first study, anti-EpCAM coupled immunoliposomes were used to target human 
cancer cells in vitro. Large unilamellar vesicles were sterically stabilized by using a 
pegylated phospholipid (Kirpotin, Park et al., 1997) and then, covalently coupled to a 
commercial anti-EpCAM antibody using a phospholipid linker. Subsequently, pure melittin 
was incorporated into the immunoliposome mixture. Unbonded peptide was separated by 
gel filtration chromatography. For the complete protocol, see reference (Barrajón-Catalán, 
Menéndez-Gutiérrez et al., 2010). 
Once immunoliposomes were obtained, the expression levels of EpCAM were analyzed in 
the cell lines. In this case, the selected cell lines were MCF7 and MDA-MB231, both derived 
from a pleural effusion of a human breast adenocarcinoma; MCF7 is documented to have 
high expression levels of EpCAM. On the contrary, MDA-MB231 shows a very low 
expression (Prang, Preithner et al., 2005). To ensure this point, EpCAM expression was 
analyzed by Western blot using an anti-EpCAM antibody (Figure 2) in both cell lines, 
confirming the previously published results. 
 
 
Fig. 2. Anti-EpCAM Western blot showing the expression levels of the protein in MCF7 and 
MDA-MB231 cells. Molecular weight references (in kDa) are shown in the left side of the 
picture. 
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To ensure that targeted antigen is mainly expressed as a surface protein instead of being 
located in endosomes or vacuoles, and that it can be reached by the antibodies linked to the 
LILs, fluorescence-activated cell sorting (FACS), a type of flow cytometry, can be used. 
Membrane expression levels of surface antigens can be measured and compared using this 
sensitive technique. Other alternative is to perform Western blot analysis of membrane 
protein extracts obtained after subcellular fractionation. One example of the results obtained 
by FACS is shown in figure 3, where EpCAM membrane expression levels in MCF7 and 
MDA-MB231 cell lines are compared. 
 
 
Fig. 3. Analysis of EpCAM expression on cell membranes by FACS in MDA-MB231 (grey) 
and MCF7 (black). 
Once the expression levels of the chosen antigen have been determined in both cell lines, 
binding of immunoliposomes to the cells can be assessed by fluorescence microscopy. For this 
purpose, the lipid mixture can be labeled using a fluorescent phospholipid conjugated with 
rhodamine. Alternatively, fluorescein isothiocyanate (FTIC) conjugated antibodies can also be 
used. In the present example, images of two cell lines were obtained after treatment with 
fluorescent immunoliposomes, which were labeled both with rhodamine conjugated 
phosphatidylethanolamine (PE) and anti-EpCAM FTIC-conjugated (Figures 4A and 4B). MCF7 
cells, which overexpress EpCAM antigen, present a double labeling due to the binding of 
complete immunoliposomes (red of rhodamine-PE and green of FITC-labeled antibody). 
However, MDA-MB231 cells showing low EpCAM expression levels present only a weak red 
fluorescence due to the background signal deriving from rhodamine-labeled liposomes 
lacking the antibody. The cytotoxic activity of the LILs can be also analyzed using fluorescence 
microscopy or flow cytometry. Some probes, such as DAPI are able to penetrate only in 
permeabilized cells or cells with damaged membranes, then these probes are specific for cell 
death. The efficacy of the cytotoxic effect of LILs may be also monitorized using DAPI 
fluorescence because of the effect of lytic peptides on cell membrane (Figure 4C). MCF7 cells 
show a triple-labeling (red from lipids, green from antibody and blue from DAPI), indicating 
that the binding of the LILs to the targeted cells is followed by cell death. 
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Fig. 4. Fluorescence microscopy imaging of the treatment of breast cancer cells with LILs 
containing EpCAM antibody. MCF7 (A) and MDA-MB231 (B) cells treated with LILs 
carrying  rhodamine conjugated PE and anti-EpCAM FTIC conjugated antibody. (C) MCF7 
cells treated with the same LILs but in the presence of DAPI (blue fluorescence). 
Fluorescent microscopy imaging is a useful technique for obtaining qualitative results, 
nevertheless quantification of the binding and cytotoxic effects of LILs are key aspects to 
consider in order to test LILs efficacy. The use of flow cytometry is a great approach to 
quantify these two aspects simultaneously. To achieve this goal, LILs carrying FITC-
conjugated EpCAM antibody were used to treat both cell lines and then propidium iodine, 
which only penetrates permeabilized cells, was added to monitorize cell death. Figure 5 
shows the treatment of MDA-MB231 and MCF-7 cells using labeled LILs and propidium 
iodine. The whole bar indicates the percentage of EpCAM FITC labeled cells and stripped 
bar shows dead cells (propidium iodine labeled), which are EpCAM positive, i.e. cells 
showing double labeling. EpCAM overexpressing MCF7 cells treated with LILs showed ten 
times more fluorescence, due to antibody labeling, than MDA-MB231 cells, which showed a 
low EpCAM expression level (Figure 5). This indicates that MCF7 cells were succesfully 
reached by LILs. Furthermore, only MCF7 cells were labeled with propidium iodine, 
indicating that the binding of LILs to these cells was followed by permeabilization and cell 
death. This confirms previous fluorescence microscopy results. 
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Fig. 5. Flow cytometry results of MDA-MB231 and MCF-7 cells treated with LILs carrying 
EpCAM antibody and propidium iodine. Total bars indicate the percentage of EpCAM 
positive-expressing cells while stripped fraction of the bars indicates the percentage of these 
cells reached by propidium iodine. 
Other techniques to quantify the effects of LILs on cancer cells are those focused to 
determine cell viability. MTT (Barrajon-Catalan, Fernandez-Arroyo et al., 2010) and violet 
crystal are among the techniques most commonly used for detecting cell survival. Adequate 
control experiments must also be established in cell survival assays in order to obtain 
conclusions about LILs specificity. Target cells must be treated comparatively, using 
identical concentrations of either complete LILs (LILs carrying labeled antibody and lytic 
peptide), with immunoliposomes lacking the lytic peptide (LIP), or with liposomes bearing 
the lytic peptide but lacking the antibody (LIP + LP) (Figure 6). Although some level of 
unspecific cytotoxicity was found in the cells showing low antigen expression levels (MDA-
MB231), LILs exerted a strong cytotoxic effect on cells expressing high levels of EpCAM, 
which demonstrates LILs selectivity. 
 
 
Fig. 6. Survival plots for two breast cancer cell lines having different EpCAM expression 
levels treated with various liposomal systems. Percentage of surviving cells was measured 
by MTT assay. MCF7 (dotted bars) and MDA-MB231 cells (white bars) were challenged with 
different constructs of liposomes and LILs. 
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3.2 HER2 immunoliposomes 
HER2 molecule is probably the most studied and clinically used target in anticancer studies 
involving immunotherapies. HER2 (or ErbB2) is a protooncogene belonging to the 
epidermal growth factor receptor family (EGFR or ErbB) of receptor tyrosine kinases (RTK) 
(Olayioye, Neve et al., 2000). HER2 is overexpressed in 20–30% of breast and ovarian cancers 
(Slamon, Clark et al., 1987). Moreover, in normal adult tissues, HER2 is present only at low 
levels in certain epithelial cell types (Press, Cordon-Cardo et al., 1990). Several anticancer 
therapies targeting ErbB receptors have been developed, and the humanized monoclonal 
antibody that binds to HER2 (Herceptin® or trastuzumab) is currently in clinical use as an 
effective treatment for HER2 positive breast cancer (Slamon, Leyland-Jones et al., 2001). 
Trastuzumab has been used in several therapeutical approaches coupled to liposomes in 
order to increase anticancer therapy selectivity. Anti-HER2 immunoliposomes have shown 
binding and internalization capacities in HER2-overexpressing cells (Kirpotin, Park et al., 
1997), which leads to intracellular drug delivery. Moreover, the use of doxorubicin-loaded 
anti-HER2 immunoliposomes exhibited significantly better therapeutic results, in HER2-
overexpressing xenograft models, compared to other treatments (Park, Hong et al., 2002). 
The cellular model presented above for EpCAM LILs was composed of two cell lines, but 
more complex models can be used when several cell lines with different antigen expression 
levels are available. Figure 7 shows the level of HER2 expression of the total cellular extracts  
 
 
Fig. 7. HER expression level of four breast cancer cells by Western blot analysis. Top image 
shows the expression level in total cellular extracts from the different cell lines (MCF7, 
MCF7/HER2, SKBr3 and JIMT-1). Bottom image shows the results of the quantification of 
the bands using densitometric analysis. MCF7 and SKBr3 derive from a pleural effusion of a 
human breast adenocarcinoma, MCF7/HER2 stably overexpress HER2 after transfection 
and JIMT-1 derives from a human breast cancer clinically resistant to trastuzumab 
(Barrajón-Catalán, Menéndez-Gutiérrez et al., 2010). 
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deriving from four different breast cancer cell lines (Barrajón-Catalán, Menéndez-Gutiérrez 
et al., 2010). Western blot analysis and quantification of the bands by densitometric analysis 
showed that MCF7/HER2 and SkBr3 exhibited the highest HER2 expression levels followed 
by JIMT-1 and MCF7 cells. 
Nevertheless, to confirm the extracellular location of the antigen detected by Western blot, 
flow cytometry analysis using an antiboby able to detect only the antigen on the cell 
membrane was also performed. In this case, the different expression level of each cell line 
correlates to a displacement of the peak population to higher fluorescent levels, as shown in 
Figure 8. 
 
 
Fig. 8. FACS analysis of membrane HER2 expression in different breast cancer lines, named 
in the histograms. 
The efficacy and selectivity of HER2-containing LILs on the different cell lines were tested in 
dose/response experiments using increasing concentrations of the LILs. Viability of MCF7 
cells (with low HER2 expression) was the least affected by LILs. JIMT-1 cells viability was 
decreased in a higher degree than that one observed for MCF7 cells. Besides, MCF7/HER2 
and SKBr3 cells, showing the highest levels of HER2 expression, underwent a sharp 
decrease of their viability at almost all the concentrations of the immunoliposomes 
preparation studied. Therefore, the higher the expression of HER2 was, the more active LILs 
system was (Figure 9A). Nevertheless, high concentrations of immunoliposomes would 
make the cytotoxic activity to be less cell-specific. Therefore, the biggest differences in cell 
viability were found at 0.3 mM total lipid concentration (Figure 9B). 
Flow cytometry experiments using specific probes for cell death are good complementary 
information to cell viability assays. However, new technical approaches as ImageStream 
analysis allow, not only the quantification of the fluorescence probes, but also obtaining in 
situ fluorescent images of the treated cells, when lipid or antibodies are labeled with 
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fluorescent dyes. ImageStream-based analysis employs flow cytometry combined with 
microscopy and allows for statistical analysis of a variety of cellular parameters, as well as 
the visualization of cells in suspension during flow analysis via high-resolution bright-field, 
dark-field and fluorescence images (Zuba-Surma, Kucia et al., 2007). 
 
 
 
Fig. 9. Survival assays for HER2 LILs. (A) Plots showing the percentage of viable cells in 
each breast cancer cell line as determined by MTT assay after treatment with HER2 labeled 
LILs (---- JIMT-1, -▲- MCF7/HER2, -○- SKBr3, - ■- MCF7). (B) Percentage of viable cells 
determined by MTT assay for the four breast cancer cell lines after the treatment with 0.3 
mM of LILs (AbDR) or immunoliposomes lacking the lytic peptide (AbDR-ø). 
Figure 10 shows the ImageStream assay results of the treatment of SkBr3 breast cancer cells 
with liposomes containing a rhodamine labeled lipid, but lacking antibody (Rhod-L, panel 
A) in comparison to labeled liposomes bearing HER antibody (Rhod-LILs, panel B) 
(Barrajón-Catalán, Menéndez-Gutiérrez et al., 2010). For quantification purposes, cell 
populations were separated in three different groups (subpopulations number 1, 2, and 3) 
attending to increasing fluorescence intensity signal. Figure 10 shows that Rhod-L (panel A) 
and Rhod-LILs (panel B) treated cells evidenced similar subpopulation 1 (those cells having 
lowest intensity and Rhod labeling). In contrast, Rhod-LILs treated cells showed a greater 
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cell subpopulation 2 than Rhod-L treated cells (around double, i.e. 28% vs. 14%) (see panels 
A and B and quantification in panel C). Moreover, Rhod-LILs treated cells showed another 
cell subpopulation, which supposed 5% of total cells (subpopulation 3, panel B), bearing a 
very strong Rhod labeling intensity, which was negligible in Rhod-L treated cells. The 
images corresponding to examples of sorted cells deriving from both treatments (Figure 10) 
clearly showed that subpopulations 2 and 3 exhibited a strong rhodamine labeling signal, 
which demonstrates the higher specificity of Rhod-LILs for SKBr3 cells. The total 
fluorescence in Rhod-LILs treated cells was approximately three times higher than that one 
of Rhod-L treated cells. 
 
 
Fig. 10. (A and B) ImageStream results. SkBr3 breast cancer cells treated with liposomes 
containing a rhodamine labeled lipid, but lacking antibody (Rhod-L, panel A) in comparison 
to treatment with labeled liposomes bearing HER antibody (Rhod-LILs, panel B). 1, 2 and 3 
are mean cell subpopulations having increasing fluorescence intensity signal derived from 
Rhod labeling. Composite images of dark-field (DF), bright-field (BF) and rhodamine 
fluorescence (Rhod) images are shown for both conditions. (C) Gated subpopulation 2 in 
Rhod-L and Rhod-LILs treated cells. 
3.3 LILs potential mechanism 
The cytotoxic effect of LILs on the tested breast cancer cells shown in these studies is quite 
fast. The main responsible molecule for this effect is the lytic peptide melittin, since 
immunoliposomes lacking melittin were devoid of such effect. Then it must be hypothesized 
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that the cytotoxic action of LILs is mediated by a cytolytic process in which cells lysis is 
present. This event occurs within a few hours. Some descriptive images were taken to show 
this action (Figure 11). The figure clearly shows that cells died in a few hours period 
suffering a presumably lytic process, showing membrane cell disruption and leading to the 
release of the intracellular content followed by cell membrane retraction. 
 
 
 
Fig. 11. Images from a LILs treatment. Images extracted from a time-course follow up 
experiment of the treatment of MCF7/HER2 cells for 4 h with LILs in a Nikon Eclipse 
TE2000U fluorescence microscope. The images were taken a 0 (A), 1 (B), 2 (C), and 4 h (D) 
using a 20x lens. 
Apparently, apoptosis is not directly implicated in the LILs mechanism as the time-lapse is 
too short (only a few hours) and no signals of DNA fragmentation or apoptotic bodies were 
observed after DAPI labeling (Figure 12). 
LILs must be also structurally characterized by several techniques in order to test size and 
stability of the delivery system. Size, polydispersity and Z-potential can be obtained by 
Dinamic Light Scattering (Villari & Micali, 2008), a potent and simple technique that allows 
to obtain these parameters without disrupting the LILs. The quantification of the amount of 
antibody present in LILs by Western blot is also useful in order to confirm the number of 
antibody molecules per liposome, which can give information about the efficacy of the 
derivatization of liposomes (Barrajón-Catalán, Menéndez-Gutiérrez et al., 2010). 
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Fig. 12. DAPI labeling after LILs treatment. Contrast phase (A) and fluorescence images (B) 
of DAPI staining of MCF7–HER2 cells treated with LILs, images were taken using 40x lens. 
4. Conclusions 
LILs are a suitable pharmacological tool for the selective treatment of cancer cells. For their 
synthesis, liposomes containing an adequate lipid composition, and a choice of lytic peptides 
and antibody are required. LILs exhibit specific cytotoxicity against antigen overexpressing 
breast cancer cells. Moreover, this capacity correlates to the antigen expression level at the cell 
membranes. The morphological changes observed through microscopy, when cancer cells are 
treated, suggest a very fast mechanism of cell death, which might take place primarily through 
membrane pore formation involving a cytolytic process.  
The approach presented here may suppose an specific and effective strategy for the 
treatment of tumors that show overexpression of a surface antigen, by using a low toxicity 
peptide such as melittin. The examples presented in this chapter describe the elements 
needed to synthesize lytic immunoliposomes and the techniques to assay their activity on 
cancer cells. Although these studies have been focused on cancer cells, if an overexpressed 
surface antigen exists, this approach may be extended to other cell types. Finally, 
immunoliposomes could be also used as delivery systems for other cytotoxic molecules, 
either from synthetic or natural origin, which could improve the selectivity or efficacy of 
these molecules on their cellular targets. 
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